Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity por Walter Suárez Carmona | Sep 21, 2025
Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial por Walter Suárez Carmona | Sep 21, 2025
Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial por Walter Suárez Carmona | Sep 21, 2025
Glucagon-like peptide-1 receptor agonists across the cardiovascular-kidney-metabolic spectrum: One size does not fit all por Walter Suárez Carmona | Sep 21, 2025
Generative artificial intelligence–mediated confirmation biasin health information seeking por Walter Suárez Carmona | Sep 15, 2025
